Cargando…

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience

Wilms’ tumor 1 (WT1) protein is highly immunogenic and overexpressed in acute myeloid leukemia (AML), consequently ranked as a promising target for novel immunotherapeutic strategies. Here we report our experience of a phase I/II clinical trial (NCT01051063) of a vaccination strategy based on WT1 re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreutmair, Stefanie, Pfeifer, Dietmar, Waterhouse, Miguel, Takács, Ferenc, Graessel, Linda, Döhner, Konstanze, Duyster, Justus, Illert, Anna Lena, Frey, Anna-Verena, Schmitt, Michael, Lübbert, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588470/ https://www.ncbi.nlm.nih.gov/pubmed/35476127 http://dx.doi.org/10.1007/s00262-022-03202-8

Ejemplares similares

Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics
por: Javorniczky, Nora Rebeka, et al.
Publicado: (2023)

The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
por: Charlet, Anne, et al.
Publicado: (2021)

Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues
por: Gengenbacher, Anina, et al.
Publicado: (2019)

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts
por: Greve, Gabriele, et al.
Publicado: (2023)

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression
por: Gentle, Ian Edward, et al.
Publicado: (2021)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
por: Poggio, Teresa, et al.
Publicado: (2018)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia
por: Yu, Chuanjiang, et al.
Publicado: (2020)

Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy
por: van den Ancker, Willemijn, et al.
Publicado: (2013)

APC/C(Cdh1)-Mediated Degradation of the F-Box Protein NIPA Is Regulated by Its Association with Skp1
por: von Klitzing, Christine, et al.
Publicado: (2011)

Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR
por: Jakob, Lena, et al.
Publicado: (2021)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
por: Klein, Claudius, et al.
Publicado: (2016)

Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation
por: Waterhouse, Miguel, et al.
Publicado: (2022)

The epigenetics of breast cancer – Opportunities for diagnostics, risk stratification and therapy
por: Schröder, Rieke, et al.
Publicado: (2021)

Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
por: Stomper, Julia, et al.
Publicado: (2021)

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
por: Rettig, Andrés R., et al.
Publicado: (2021)

Correction to: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
por: Stomper, Julia, et al.
Publicado: (2021)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Role of Immunomodulation of BCG Therapy on AML Remission
por: Kennedy, Alice, et al.
Publicado: (2021)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation
por: Meier, Ruth, et al.
Publicado: (2022)

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST)
por: Rassner, Michael, et al.
Publicado: (2023)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2020)

Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2021)

Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination
por: Busse, Antonia, et al.
Publicado: (2010)

Cks1 Is Required for Tumor Cell Proliferation but Not Sufficient to Induce Hematopoietic Malignancies
por: Kratzat, Susanne, et al.
Publicado: (2012)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment
por: Bunaciu, Rodica P., et al.
Publicado: (2017)

Novel combined variants of WT1 and TET2 in a refractory and recurrent AML patient
por: Ma, Qiang, et al.
Publicado: (2021)

Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing
por: Riba, Julian, et al.
Publicado: (2016)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l0hqqmsrepaejbajbkvivav4qm